capAI (LSE:CPAI), the applied artificial intelligence venture platform, announced it has entered into a licence and option agreement with R42 Group for Ageotype, an AI-powered longevity and preventative health data platform.
The deal marks capMedical's first platform since the division was incorporated in October 2025, and follows licensing talks with R42 first flagged in February.
Under the agreement, capAI holds an exclusive worldwide licence to develop and commercialise Ageotype, plus a discretionary option to acquire the underlying intellectual property for £2 million.
The licence runs 12 months from signing, expiring 22 July 2027, and R42 will take 20% of net proceeds from any future monetisation once the option is exercised, terms consistent with capAI's other R42 agreements. The agreement falls under the pair's May 2025 strategic alliance to incubate AI technologies in media and medicine.
Because R42 is led by capAI's Executive Chairman, Professor Ronjon Nag, the deal is a related party transaction under DTR 7.3, approved only by independent directors Jack Allardyce, Sarah Jane Davy and Marcus Yeoman, with Nag recused throughout.
Nag said Ageotype "integrates a genuinely broad set of health data, imaging, blood biomarkers, metabolomics and the microbiome, into a single longevity picture", giving capAI a foundation for its preventative health offering.
capAI said it continues to evaluate further capMedia and capMedical opportunities, mostly from R42's existing portfolio, though these discussions remain at an early stage.
News Intelligence what this means for the company
capAI has licensed the Ageotype longevity platform from R42 Group, securing exclusive worldwide rights to develop and commercialise it plus a £2 million option to acquire the underlying IP. This is capMedical's first platform since the division's October 2025 incorporation, extending capAI's R42 partnership—which already covers media platforms—into healthcare, though the 12-month licence term (expiring July 2027) means a near-term decision point on whether to exercise the acquisition option.
capAI is building a portfolio of licensed AI platforms across media and now healthcare, but remains in early commercialisation phases with no disclosed revenue or user traction from any platform. The Ageotype deal follows the same R42 structure as prior media licences—12-month runway, £2m IP acquisition option, 20% revenue share to R42—so it does not materially alter the company's capital requirements or deal economics, only expand the addressable market into preventative health.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
